285 related articles for article (PubMed ID: 15714077)
1. Individualization of long-term enzyme replacement therapy for Gaucher disease.
Andersson HC; Charrow J; Kaplan P; Mistry P; Pastores GM; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ;
Genet Med; 2005 Feb; 7(2):105-10. PubMed ID: 15714077
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic goals in the treatment of Gaucher disease.
Pastores GM; Weinreb NJ; Aerts H; Andria G; Cox TM; Giralt M; Grabowski GA; Mistry PK; Tylki-Szymańska A
Semin Hematol; 2004 Oct; 41(4 Suppl 5):4-14. PubMed ID: 15468045
[TBL] [Abstract][Full Text] [Related]
3. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
4. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
5. Imiglucerase treatment in Gaucher's disease.
Shah U; Nadeem N; Husen Y; Fadoo Z
J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722
[TBL] [Abstract][Full Text] [Related]
6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
7. Imiglucerase and its use for the treatment of Gaucher's disease.
Weinreb NJ
Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
[TBL] [Abstract][Full Text] [Related]
8. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
Goldwater RS
J Intraven Nurs; 1996; 19(2):83-8. PubMed ID: 8852168
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
11. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
[TBL] [Abstract][Full Text] [Related]
13. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE; vom Dahl S; Aerts JM; Belmatoug N; Bembi B; Cohen Y; Collin-Histed T; Deegan P; van Dussen L; Giraldo P; Mengel E; Michelakakis H; Manuel J; Hrebicek M; Parini R; Reinke J; di Rocco M; Pocovi M; Sa Miranda MC; Tylki-Szymanska A; Zimran A; Cox TM
Blood Cells Mol Dis; 2010 Jan; 44(1):41-7. PubMed ID: 19804996
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease: an overview of clinical characteristics and therapy.
Kingma W
J Intraven Nurs; 1996; 19(2):79-82. PubMed ID: 8852167
[TBL] [Abstract][Full Text] [Related]
15. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
17. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
18. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
Starzyk K; Richards S; Yee J; Smith SE; Kingma W
Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
[TBL] [Abstract][Full Text] [Related]
20. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
